Overall survival outcomes in MATTERHORN trial support perioperative durvalumab plus chemotherapy as standard of care.

Adding the CDK4/6 inhibitor abemaciclib to endocrine therapy significantly improves overall survival in node-positive, ...

Midwives and family physicians are essential to support mothers facing hypogalactia and maintain WHO-recommended exclusive ...

Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of ...

Additional early research suggested that combining metformin and clemastine may promote remyelination, offering hope for ...

The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who ...

The EMA says a study did not show clinical benefit, while Sanofi says it will continue to work closely with the regulator to bring the treatment to patients.

The European medicines regulator said that a higher rate of death and disease complications in recent trials meant the ...

Saphnelo can now be administered subcutaneously rather than intravenously following the European regulator’s recommendation.

From prior authorization hurdles to quantity caps, insurance restrictions on antiemetics are common and inconsistent across plans, drugs, and states, new data show.

A spectrum labeling system rating foods from least to most healthy can promote healthier food purchases than other ...

General anesthesia leads to better functional outcomes than conscious sedation in stroke patients with large vessel occlusion ...